Rationale for Using Cryocompression to Prevent Chemo-Induced Neuropathy

Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.

Mary Katherine Montes de Oca, MD, spoke with CancerNetwork® in an interview at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer about the mechanism of action for cryocompression as an intervention for preventing peripheral neuropathy associated with chemotherapy for patients with gynecologic cancers.

Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, indicated that cryocompression is a treatment that combines 2 strategies: compression therapy and cryotherapy on the patients’ hands and feet. By inducing vasoconstriction through this process, Montes de Oca states that cryocompression may reduce the likelihood of cytotoxic agents reaching the hands and feet that may cause neuropathy.

Data from a self-controlled trial indicated that patients who underwent cryocompression less frequently experienced moderate to severe symptoms of neuropathy compared with those who did not receive the intervention. At baseline, neuropathy symptoms were identified in 2.2% of cases where cryocompression was not used compared with 3.3% where it was used. At final assessment, the rate of neuropathy symptoms was 13.2% and 7.7% in each respective group.

Transcript:

Cryocompression is a combination of cold therapy and compression therapy on the hands and feet. The proposed mechanism is that the cold therapy and the compression therapy cause vasoconstriction, which then leads to decreased blood circulation to the hands and the feet, and then decreased delivery of chemotherapy or neurotoxic agents that cause neuropathy to the hands and feet.

There are a few options for the prevention of neuropathy. There are some medications that can be used for treatment once a patient is diagnosed with neuropathy. But for prevention, the only other intervention that has really shown promise is cryotherapy—just the cold therapy without the compression therapy. The goal of this study was to look at the two combined.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Related Videos
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.